Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

Authors: Bente Langdahl, Cesar Libanati, Daria B. Crittenden, Michael A. Bolognese, Jacques P. Brown, Nadia Daizadeh, Eva Dokoupilová, Klaus Engelke, Joel S. Finkelstein, Harry K. Genant, Stefan Goemaere, Lars Hyldstrup, Esteban Jódar-Gimeno, Tony M. Keaveny, David L. Kendler, Péter Lakatos, Judy Maddox, Jorge Malouf, Fabio Massari, José Fernando Molina, María Rosa Ulla, Andreas Grauer - The Lancet 2017 cited by 467